Compare Eli Lilly And Co (LLY) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Atlassian Corporation PLC — how do they compare? Eli Lilly And Co trades at $1,210.9 (market cap $1.08T), while Atlassian Corporation PLC trades at $152.55 (market cap $39.10B). The key difference: Eli Lilly And Co is far larger — about 27.6× Atlassian Corporation PLC's market cap, and Eli Lilly And Co pays a 0.57% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| LLY | TEAM | |
|---|---|---|
Market Cap | $1.08T | $39.10B |
Sector | Health | Technology |
52-Week High | $1.24K | $182.36 |
52-Week Low | $639.43 | $57.15 |
Enterprise Value | $1.13T | $39.09B |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Atlassian (TEAM) stock trades at $151.87, up 1.88% today and near its 52-week high, reflecting strong momentum after a 35% surge post-Q4 earnings. The company reported 28% revenue growth to $1.77 billion, beating estimates, with cloud revenue accelerating to 31%. Technical indicators show bullish moving averages but overbought RSI levels, while fundamentals highlight robust growth amid negative net margins. Analyst sentiment is overwhelmingly positive, with 67% buy ratings and a $161.93 consensus target.
Outlook remains favorable driven by enterprise deal expansion and AI platform adoption, though risks include high valuation multiples (P/S 6.1, EV/EBITDA 184.26) and persistent net losses. Investors should weigh growth prospects against profitability challenges and market volatility. The stock's proximity to all-time highs suggests cautious optimism is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
